About
Robert Lyne is Chief Executive Officer and a board member of PureTech Health, a publicly listed biotherapeutics company with a hub-and-spoke model that creates and advances therapeutic programs through founded entities. He joined PureTech as Chief Portfolio Officer in January 2024, became Interim CEO in July 2025, and was appointed CEO in December 2025. Before PureTech, he was CEO of Arix Bioscience and previously worked at Touchstone Innovations and Bird & Bird LLP.
Areas of interest
biotechlife sciencesdrug developmentventure capitalportfolio managementcapital marketstherapeutics